Eine konsensus-erklarung der European Psychiatric Association (EPA) zu kardiovaskularen erkrankungen und diabetes bei patienten mit einer schweren psychischen erkrankung

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156 (11): 1686–96. 2. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med 2009; 36 (4): 341–50. 3. Álvarez-Jiménez M, Hetrick S, GonzálezBlanch C, Gleeson J, McGorry P. Non-pharmacological management of antipsychoticinduced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008; 193: 101–7. 4. American Association of Clinical Endocrinologists 2007. Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. AACE Diabetes Mellitus Guidelines. Endocr Pract 2007; 13 (Suppl. 1): 3–68. 5. American Diabetes Association. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27: 596–601. 6. American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care 2009; 32 (Suppl. 1): S13–61. 7. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2009; 32 (Suppl. 1): S63–7. 8. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68 (2–3): 167–81. 9. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, et al. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr Res 2008; 104 (1-3): 1–12. 10. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, et al. Minimising metabolic and cardiovascular risk in schizophrenia. J Psychopharmacol 2007; 21 (4): 357–73. 11. Bech P, Vendsborg PJ, Rafaelson OJ. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiatr Scand 1976; 53: 70–81. 12. Berken GH, Weinstein DO, Stern WC. Weight gain: a side effect of tricyclic antidepressants. J Affect Disord 1984; 7: 133–8. 13. Bjorntorp P. Stress and cardiovascular disease. Acta Physiol Scand Suppl 1997; 640: 144–8. 14. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007; 90 (1– 3): 162–73. 15. Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs 2009; 23 (7): 583–602. 16. Brown LC, Majumdar SR, Newman SC, Johnson JA. History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care 2005; 28: 1063–7. 17. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502–8. 18. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212–7. 19. Bruggeman R, Schorr S, Van der Elst K, Postma M, Taxis K. Costeffectiveness of screening for diabetes in a cohort of patients with schizophrenia. Schizophr Res 2008; 102 (1-3): 161–2. 20. Buckley PF, Miller DD, Singer B. Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79: 281–8. 21. Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007; 68 (11): 1682–90. 22. Cahn W, Ramlal D, Bruggeman R, de Haan L, Scheepers FE, van Soest MM, et al. Prevention and treatment of somatic complications arising from the use of antipsychotics. Tijdschr Psychiatr 2008; 50 (9): 579–91. 23. Canadian Diabetes Association. Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32 (Suppl. 1): S1–20. 24. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: An